Welcome to our dedicated page for Biolife Solutions SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking BioLife’s cryopreservation revenue or CGT logistics risks in a 300-page filing can drain hours. BioLife Solutions insider trading Form 4 transactions hide in dense tables, while critical 8-K updates on clinical-trial shipments surface without warning. If you have ever wondered, “How do I locate BioLife Solutions’ quarterly earnings report 10-Q filing in seconds?” Stock Titan delivers the answer.
Our platform ingests every submission the moment it hits EDGAR and feeds it to an AI engine that turns jargon into clarity. Need a BioLife Solutions annual report 10-K simplified? We highlight consumable sales growth, supply-chain quality metrics, and major risk factors. Looking for BioLife Solutions Form 4 insider transactions real-time? Instant alerts show which executives added shares. The AI also tags each BioLife Solutions proxy statement executive compensation section, unpacks option grants, and links them to performance goals. From BioLife Solutions earnings report filing analysis to a plain-English explainer of every BioLife Solutions 8-K material events explained, the information arrives ready to use.
Professionals rely on these insights to compare consumable-driven gross margins, monitor BioLife Solutions executive stock transactions Form 4 before therapy milestones, and evaluate liquidity through each BioLife Solutions SEC filings explained simply. Whether you are understanding BioLife Solutions SEC documents with AI for the first time or fine-tuning a DCF model, Stock Titan’s real-time coverage, AI-powered summaries, and historical archive of every filing form provide the edge you need—no more hunting through PDFs for the numbers that move CGT markets.
BioLife Solutions Inc. (BLFS) – Form 4 insider transaction
Chief Human Resources Officer Sarah Aebersold reported the sale of 711 shares of common stock on 16 June 2025 at a price of $22.23 per share. The transaction was executed under a pre-arranged Rule 10b5-1(c) trading plan that became effective 11 December 2024, indicating the sale was scheduled in advance and not triggered by undisclosed information.
Following the sale, Aebersold’s direct ownership stands at 78,721 shares. Calculations from the disclosed data show the disposal represents roughly 0.9 % of her prior position (79,432 shares), suggesting only a modest reduction in personal exposure to the company’s equity.
No derivative securities were bought or sold and no additional transactions were reported. The filing contains no information about company operations, earnings, or strategic initiatives; it purely documents a routine insider trade.
FAQ
What is the current stock price of Biolife Solutions (BLFS)?
What is the market cap of Biolife Solutions (BLFS)?
What is the primary focus of BioLife Solutions Inc?
Which core business areas does the company operate in?
How does BioLife Solutions support the cell and gene therapy industry?
What makes the company’s technology unique?
How does the company ensure quality and safety in its products?
What strategic shifts has BioLife Solutions made in recent years?
How does the company maintain its competitive edge?
What industries are primarily served by BioLife Solutions?
How is the cloud-based cold chain management app beneficial?
What role does operational excellence play in the company’s success?
